Companies · Software / Tech
WASHINGTON, D.C. · Software / Tech · refined from filed group “Other” · https://www.juullabs.com/
Diligence memoA one-page analyst read on JUUL Labs, Inc. — recommendation, valuation, rhythm, risks.→JUUL Labs, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the technology sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
JUUL Labs, Inc. is one of 3920 Software / Tech companies tracked from WASHINGTON, D.C.. By capital raised it ranks among the largest (ahead of 100% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Juul Labs is on a mission to transition the world’s billion adult smokers away from combustible cigarettes, eliminate their use, and combat underage usage of our products.
Juul Labs is on a mission to transition the world’s billion adult smokers away from combustible cigarettes, eliminate their use, and combat underage usage of our products. © 2026 JUUL Labs, Inc. All rights reserved. JUUL, Juul Labs, and other JUUL brands are trademarks of JUUL Labs, Inc. The Juul Labs corporate website is intended as an informational resource regarding the company, our mission, policies, and practices. It is not intended as a consumer or commercial site. All information presented on JuulLabs.com is in strict accordance with the regulations governing tobacco products established by the U.S. Food and Drug Administration and Centers for Disease Control and Prevention. The sale of tobacco products to minors is prohibited by law. Warning: This product contains nicotine. Nicotine is an addictive chemical. California Proposition 65 Warning: This product contains chemicals known to the state of California to cause cancer and birth defects or other reproductive harm. California Transparency in Supply Chains Act Juul Labs is committed to providing accessible products and services. If you have a question or comment about accessibility at Juul Labs, please contact us . We stri
Trades publicly as Home • Juul Labs.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 71%.
Round size and date are reported; the stage label is inferred from round size (latest is Growth/Late — a round over $400M). Valuation is modeled from stage benchmarks scaled by the technology sector profile. Directional, not a quoted figure.
Benchmarked against 3920 companies in Software / Tech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 100% of sector peers (real $). Modeled value above 100% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Growth/Late) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #1 of 6.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| JUUL Labs, Inc. this company | Growth/Late | $4.4B | $31.3B | 3.84× |
| Jingbo Technology, Inc. | Growth/Late | $1.5B | $19.1B | 2.34× |
| Yuga Labs, Inc. | Growth/Late | $424.1M | $9.6B | 1.17× |
| Sanborn Analytics Inc | Growth/Late | $500.0M | $6.7B | 0.83× |
| Pagaya Technologies Ltd. | Growth/Late | $3.5B | $1.3B | 0.16× |
| ROM Technologies, Inc. | Growth/Late | $952.2M | $62.8M | 0.01× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $3.2M | 2011-05-04 | $16.2M | $110.1M | 85% |
| Series C | $46.7M | 2015-03-24 | $311.2M | $1.5B | 85% |
| Series A | $6.5M | 2015-03-24 | $29.5M | $180.3M | 85% |
| Series C | $55.0M | 2016-12-19 | $366.7M | $1.7B | 90% |
| Series A | $4.4M | 2016-12-19 | $19.9M | $121.5M | 90% |
| Series D+ | $111.5M | 2017-12-04 | $929.2M | $3.5B | 90% |
| Growth/Late | $650.0M | 2018-06-26 | $6.5B | $21.2B | 90% |
| Series D+ | $325.0M | 2019-08-02 | $2.7B | $10.3B | 90% |
| Growth/Late | $785.2M | 2019-08-02 | $7.9B | $25.6B | 90% |
| Growth/Late | $721.6M | 2020-02-03 | $7.2B | $23.5B | 90% |
| Growth/Late | $1.3B | 2023-10-27 | $12.7B | $20.1B | 90% |
| Growth/Late | $2.0B | 2023-10-27 | $19.8B | $31.3B | 90% |
| Growth/Late | $1.3B | 2023-10-27 | $12.8B | $20.2B | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Hoyoung Huh | — | 6 other | 2017-12 |
| Riaz Valani | — | 4 other | 2011-05 |
| Kevin Burns | — | 3 other | 2017-12 |
| Zachary Frankel | — | 2 other | 2017-12 |
| Adam Bowen | — | 1 other | 2011-05 |
| James Monsees | — | 1 other | 2011-05 |
| Saurabh Sinha | — | 1 other | 2020-02 |
| Ashley Gould | — | — | 2016-12 |
| David Barse | — | — | 2023-10 |
| Gerald Masoudi | — | — | 2018-06 |
| Harold Handelsman | — | — | 2015-03 |
| Joel Klein | — | — | 2023-10 |
| K.C. Crosthwaite | — | — | 2020-02 |
| Nicholas Pritzker | — | — | 2015-03 |
| Paul Aronzon | — | — | 2023-10 |
| Timothy Danaher | — | — | 2016-12 |
| Tom Dykstra | — | — | 2011-05 |
| Tyler Goldman | — | — | 2016-12 |
| Tyler Mace | — | — | 2023-10 |
| Vittal Kadapakkam | — | — | 2023-10 |
JUUL Labs, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| PAX Labs, Inc. | Software / Tech | Growth/Late | $445.7M | $14.5B | network2 shared operators · same sector · same stage |
| Pagaya Technologies Ltd. | Software / Tech | Growth/Late | $3.5B | $1.3B | same sector · same stage |
| Palantir Technologies Inc. | Software / Tech | Growth/Late | $2.5B | $17.9B | same sector · same stage |
| Foundation Technology Worldwide LLC | Software / Tech | Growth/Late | $2.5B | $6.5B | same sector · same stage |
| Marvell Technology, Inc. | Software / Tech | Growth/Late | $2.2B | $1.9B | same sector · same stage |
| Beta Technologies Inc. | Software / Tech | Growth/Late | $1.6B | $3.2B | same sector · same stage |
| Jingbo Technology, Inc. | Software / Tech | Growth/Late | $1.5B | $19.1B | same sector · same stage |
| Ramp Business Corp | Other Technology | Growth/Late | $2.2B | $3.1B | network1 shared operator · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Lucy Goods, Inc Lucy’s mission is to reduce tobacco-related harm to zero. We provide… | Biotech | — | — | 75% |
| Juva Life, Inc. | Pharmaceuticals | Series A | $168.8M | 70% |
| JucaBio LLC | Other | Seed | $13.5M | 70% |
| JUVA LIFE INC./Canada | Biotechnology | Pre-Seed | $7.7M | 69% |
| Hemp2Lab, LLC | Other | Pre-Seed | $22.0M | 69% |
| CancerVAX, Inc. | Biotechnology | Pre-Seed | $7.2M | 68% |
| X-Vax Technology, Inc. | Biotechnology | Series C | $2.3B | 68% |
| Smoke-i Corp | Other | Pre-Seed | $12.0M | 67% |
See where JUUL Labs, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at JUUL Labs, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.